[go: up one dir, main page]

GB202110825D0 - Methods for assessing epigenetic age and cancer risk - Google Patents

Methods for assessing epigenetic age and cancer risk

Info

Publication number
GB202110825D0
GB202110825D0 GBGB2110825.3A GB202110825A GB202110825D0 GB 202110825 D0 GB202110825 D0 GB 202110825D0 GB 202110825 A GB202110825 A GB 202110825A GB 202110825 D0 GB202110825 D0 GB 202110825D0
Authority
GB
United Kingdom
Prior art keywords
methods
cancer risk
epigenetic age
assessing
assessing epigenetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2110825.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB2110825.3A priority Critical patent/GB202110825D0/en
Publication of GB202110825D0 publication Critical patent/GB202110825D0/en
Priority to PCT/GB2022/051984 priority patent/WO2023007165A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2110825.3A 2021-07-28 2021-07-28 Methods for assessing epigenetic age and cancer risk Ceased GB202110825D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2110825.3A GB202110825D0 (en) 2021-07-28 2021-07-28 Methods for assessing epigenetic age and cancer risk
PCT/GB2022/051984 WO2023007165A1 (en) 2021-07-28 2022-07-28 Methods for assessing epigenetic age and cancer risk

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2110825.3A GB202110825D0 (en) 2021-07-28 2021-07-28 Methods for assessing epigenetic age and cancer risk

Publications (1)

Publication Number Publication Date
GB202110825D0 true GB202110825D0 (en) 2021-09-08

Family

ID=77541193

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2110825.3A Ceased GB202110825D0 (en) 2021-07-28 2021-07-28 Methods for assessing epigenetic age and cancer risk

Country Status (2)

Country Link
GB (1) GB202110825D0 (en)
WO (1) WO2023007165A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1223981A1 (en) * 2012-11-09 2017-08-11 加利福尼亚大学董事会 Methods for predicting age and identifying agents that induce or inhibit premature aging
EP3864174B1 (en) * 2018-10-08 2024-12-04 Thomas J.C. Matzen GmbH Method and devices for age determination
GB201908591D0 (en) * 2019-06-14 2019-07-31 Ucl Business Plc Methods for cancer diagnosis
GB201908624D0 (en) * 2019-06-17 2019-07-31 Vib Vzw Predicting age using dna methylation signatures

Also Published As

Publication number Publication date
WO2023007165A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
EP3794348A4 (en) Cell-free dna for assessing and/or treating cancer
IL279774A (en) Methods and apparatus for assessing embryo development
EP3792363C0 (en) Method and kit for identifying lung cancer status
SG11202100744VA (en) Methods and apparatuses for reading blockchain data
SG11202103913WA (en) Method for quantifying molecular activity in cancer cells of a human tumour
IL304275A (en) Methods for treating cancer
GB202014920D0 (en) Methods for treating cancer and autoimmune and inflammatory diseases
IL312680A (en) Methods for treating cancer
IL284827A (en) Biomarker panel for diagnosis and prognosis of cancer
GB202116650D0 (en) Methods for enabling secured and personalised genomic sequence analysis
GB202215887D0 (en) Methods and systems for determining pigmentation phenotypes
IL288970A (en) Methods of detecting and predicting breast cancer
GB201915464D0 (en) Novel biomarkers and diagnostic profiles for prostate cancer
IL286791A (en) Novel psma specific binding proteins for cancer diagnosis and treatment
GB202110825D0 (en) Methods for assessing epigenetic age and cancer risk
GB202009220D0 (en) Methods for detecting and predicting cancer
EP4334718A4 (en) Assessing and treating cancer
EP3935190A4 (en) Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s)
GB202009222D0 (en) Methods for detecting and predicting cancer
GB202107412D0 (en) Methods for detecting and predicting cancer and/or CIN3
EP4271262A4 (en) Method and system for acquiring spectral data for use in assessing risk of breast cancer
ZA202105583B (en) Methods of diagnosing and treating cervical cancer
GB202006729D0 (en) Cancer screening test
GB202009224D0 (en) Methods for detecting and predicting cancer and/or cin3
GB202116412D0 (en) Methods for detecting and predicting breast cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)